Xeris Biopharma Holdings (XERS) Other Non Operating Income (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Other Non Operating Income data on file, last reported at -$5.7 million in Q1 2026.

• Quarterly Other Non Operating Income rose 7.31% year-over-year to -$5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $448000.0 (up 101.78% YoY) and the FY2024 annual result came in at -$23.5 million, down 726.86% from the prior year.
• Other Non Operating Income slipped to -$5.7 million in Q1 2026, from $18.6 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $18.6 million in Q4 2025 to a low of -$7.6 million in Q3 2023.
• A 5-year average of -$4.0 million and a median of -$5.9 million in 2024 frame the typical range for Other Non Operating Income.
• Annual changes were most pronounced in 2022 — Other Non Operating Income plunged 340.28% — and 2025, when it soared 374.59%.
• Tracing XERS's Other Non Operating Income over 5 years: stood at -$3.4 million in 2022, then climbed by 17.4% to -$2.8 million in 2023, then plunged by 142.57% to -$6.8 million in 2024, then soared by 374.59% to $18.6 million in 2025, then tumbled by 130.47% to -$5.7 million in 2026.
• The last three Other Non Operating Income figures came in at -$5.7 million (Q1 2026), $18.6 million (Q4 2025), and -$6.1 million (Q3 2025), per Business Quant data.